Anxiety and depression among epilepsy patients in low-risk areas for COVID-19 in the northern part of Guizhou Province, China, during the COVID-19 pandemic

Table 4 Comparison of PHQ-9 and GAD-7 scores within the epilepsy group

	Epilepsy patients n = 200		PHQ-9	Z/χ²	P	GAD-7	Z/χ²	P
	n	%	Median (P25, P75)			Median (P25, P75)
Sex				−3.263	0.001		−2.535	0.011
Male	89	44.50	1 (0, 5)			0 (0,4)
Female	111	55.50	4 (0, 10)			3 (0,8)
Age, years				4.408	0.354		6.451	0.168
14–23	67	33.50	4 (0, 11)			2 (0,9)
24–33	77	38.50	2 (0, 7)			1 (0, 5)
34–43	28	14.00	3 (0.25, 10)			3.5 (0, 8.5)
44–53	22	11.00	0 (0, 6.5)			0 (0, 4.25)
≥ 54	6	3.00	3.5 (0.75, 9.75)			3 (0, 8)
Do you pay attention to the COVID-19’s epidemic situation every day?				−3.102	0.002		−2.287	0.022
Yes	182	91.00	2 (0, 8)			1 (0, 6)
No	18	8.00	7.5 (4, 10.5)			4.5 (1.75, 9.5)
Is life disrupted?				−1.21	0.226		−1.423	0.155
Yes	118	59.00	4 (0, 8)			3 (0, 5)
No	82	41.00	1 (0, 8.25)			1 (0, 5)
Type of medication				−0.098	0.922		−1.556	0.12
A single ASM	130	65.00	2 (0, 8)			2 (0, 5)
A combination of ASMs	70	35.00	2.5 (0, 10.25)			2.5 (0, 7.25)
Did you have seizures in the past month?				−0.91	0.363		−1.08	0.28
Yes	74	37.00	3 (0, 9.25)			3 (0, 7)
No	126	63.00	2 (0, 7.25)			1 (0, 5.25)

GAD-7 Generalized Anxiety Disorder-7, PHQ-9 Patient Health Questionnaire 9, ASM Anti-seizure medicine

ISSN: 2524-4434